Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Next Previous
X
Search
Trial Profile

A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Jun 2024 Results assessing the incidence of CHIP in cfDNA from patients with solid tumors and explored its association with outcomes and adverse events from a local prospective solid tumor cohort (PREDICT-L) and two randomized trials: CCTG CO.26 in metastatic colorectal cancer and CCTG PA.7, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 09 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
    • 20 Jan 2024 Results of pooled analysis from NCT02870920 and NCT02879318; investigating the incidence of CHIP in ctDNA from patients with gastrointestinal (GI) cancers and explored its association with outcomes and adverse events , presented at the 2024 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top